Immusoft utilizes Immune System Programming (ISP™) to reprogram a patient's B cells into plasma cells that produce therapeutic proteins, effectively creating personalized biofactories for treatment. This technology addresses the need for sustained delivery of gene-encoded medicines for rare diseases, offering long-term therapeutic benefits from the patient's own cells.
Funding
Funding not disclosed
+1Founders
Product
Problem
Current treatments for rare diseases often require frequent and invasive procedures to deliver therapeutic proteins. Sustained delivery of gene-encoded medicines remains a challenge, limiting long-term therapeutic benefits for patients.
Solution
Immusoft is developing a novel approach called Immune System Programming (ISP™) that reprograms a patient's B cells to function as personalized biofactories, producing therapeutic proteins directly within the body. The process involves collecting a patient's B cells and programming them to produce specific therapeutic proteins. These modified B cells are then expanded and differentiated into plasma cells, which are capable of producing large quantities of the desired protein. Finally, the engineered cells are infused back into the patient, where they are expected to reside and continuously produce the therapeutic protein over extended periods. This approach aims to provide a sustained and less invasive method for delivering gene-encoded medicines.
Target Audience
The primary target audience includes patients with rare diseases who require sustained delivery of therapeutic proteins, as well as clinicians and researchers focused on gene therapy and cell-based therapies.
Features
- Utilizes a patient's own B cells to minimize immune rejection.
- Programs B cells to differentiate into plasma cells, which act as protein-producing biofactories.
- Aims for sustained, long-term delivery of therapeutic proteins.
- Employs gene therapy to address the root cause of rare diseases.
- First-in-human clinical trial of genetically engineered B cells for Mucopolysaccharidosis type I (MPS I).